$379 Million is the total value of VHCP Management II, LLC's 20 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 81.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TXG | 10X Genomics Inc. | $136,215,000 | +51.3% | 1,786,431 | 0.0% | 35.91% | +4.7% | |
| AXSM | Sell | Axsome Therapeutics Inc | $81,239,000 | +349.5% | 785,981 | -12.0% | 21.42% | +210.9% |
| CNST | Buy | Constellation Pharmaceuticals | $70,695,000 | +1406.1% | 1,500,631 | +106.5% | 18.64% | +941.7% |
| BHVN | Sell | Biohaven Pharmaceuticals | $25,200,000 | -15.3% | 462,903 | -35.1% | 6.64% | -41.4% |
| SWAV | Sell | Shockwave Medical Inc | $12,686,000 | -34.4% | 288,838 | -55.3% | 3.34% | -54.6% |
| ISEE | New | Iveric Bio Inc | $8,617,000 | – | 1,004,299 | +100.0% | 2.27% | – |
| KALV | Sell | Kalvista Pharmaceuticals | $6,523,000 | +49.2% | 366,268 | -2.8% | 1.72% | +3.2% |
| OBSV | Sell | Obseva SA | $6,011,000 | -68.0% | 1,573,639 | -30.1% | 1.58% | -77.8% |
| MRSN | New | Mersana Therapeutics Inc | $5,286,000 | – | 922,514 | +100.0% | 1.39% | – |
| SPRO | Spero Therapeutics Inc | $4,558,000 | -9.3% | 474,015 | 0.0% | 1.20% | -37.2% | |
| RLMD | New | Relmada Therapeutics Inc | $4,480,000 | – | 114,876 | +100.0% | 1.18% | – |
| ADVM | New | Adverum Biotechnologies Inc | $4,419,000 | – | 383,620 | +100.0% | 1.16% | – |
| MRNS | Marinus Pharmaceuticals Inc | $3,211,000 | +40.3% | 1,486,676 | 0.0% | 0.85% | -3.0% | |
| FTSV | New | Forty Seven Inc | $3,060,000 | – | 77,714 | +100.0% | 0.81% | – |
| MIST | Milestone Pharmaceuticals Inc | $2,378,000 | -14.2% | 148,560 | 0.0% | 0.63% | -40.6% | |
| NXTC | New | Nextcure Inc | $2,042,000 | – | 36,249 | +100.0% | 0.54% | – |
| MYOV | New | Myovant Sciences Ltd | $1,191,000 | – | 76,768 | +100.0% | 0.31% | – |
| ETNB | New | 89Bio Inc | $1,084,000 | – | 41,235 | +100.0% | 0.29% | – |
| BLPH | Sell | Bellerophon Therapeutics | $230,000 | -88.5% | 659,087 | -84.1% | 0.06% | -92.0% |
| PTGX | Sell | Protagonist Therapeutics Inc | $227,000 | -95.6% | 32,211 | -92.5% | 0.06% | -96.9% |
| PRVL | Exit | Prevail Therapeutics Inc | $0 | – | -2,604 | -100.0% | -0.01% | – |
| PTI | Exit | Proteostasis Therapeutics Inc | $0 | – | -130,733 | -100.0% | -0.04% | – |
| RDUS | Exit | Radius Health Inc | $0 | – | -13,667 | -100.0% | -0.13% | – |
| TCDA | Exit | Tricida Inc | $0 | – | -118,886 | -100.0% | -1.40% | – |
| LJPC | Exit | La Jolla Pharmaceuticals | $0 | – | -518,102 | -100.0% | -1.74% | – |
| KNSA | Exit | Kiniksa Pharmaceuticals Ltd | $0 | – | -540,461 | -100.0% | -1.75% | – |
| BCRX | Exit | BioCryst Pharmaceuticals Inc | $0 | – | -2,874,602 | -100.0% | -3.14% | – |
| RARX | Exit | Ra Pharmaceuticals | $0 | – | -677,164 | -100.0% | -6.10% | – |
| ASND | Exit | Ascendis Pharma A/S | $0 | – | -234,591 | -100.0% | -8.61% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Ascendis Pharma A/S | 16 | Q3 2019 | 18.3% |
| BioCryst Pharmaceuticals Inc | 15 | Q3 2019 | 20.9% |
| Ra Pharmaceuticals | 12 | Q3 2019 | 6.4% |
| Biohaven Pharmaceuticals | 11 | Q4 2019 | 18.1% |
| Obseva SA | 11 | Q4 2019 | 12.2% |
| DBV Technologies | 10 | Q1 2018 | 11.6% |
| Kalvista Pharmaceuticals | 10 | Q4 2019 | 6.4% |
| Bellerophon Therapeutics | 10 | Q4 2019 | 3.0% |
| AveXis Inc | 9 | Q1 2018 | 32.2% |
| Edge Therapeutics Inc | 9 | Q4 2017 | 18.2% |
View VHCP Management II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-10-26 |
| 4 | 2022-10-20 |
| 4 | 2022-10-17 |
| 4 | 2022-10-11 |
| 4 | 2022-10-06 |
| 4 | 2022-10-03 |
| 4 | 2022-09-28 |
| 4 | 2022-09-07 |
| 4 | 2022-09-01 |
| 4 | 2022-08-02 |
View VHCP Management II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.